Twist Bioscience (TWST) Jumps As Guidance And Capital Raise Reset The Trade

Twist Bioscience Corporation stocks have been trading up by 12.7 percent following optimistic coverage of its genomic technology advancements.

Live Update At 12:37:40 EDT: On Wednesday, August 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 12.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience, ticker TWST, is acting like a classic high-growth story trying to cross the bridge to real profitability. Q3 revenue came in at $118.4M, ahead of roughly $114.5M estimates and up more than 23% year over year. That kind of top-line growth is why traders crowd into names like TWST when momentum flips on.

But the other side of the tape matters. TWST posted a Q3 loss of $0.56 per share, deeper than last year’s $0.33 loss, and key profitability ratios are still negative. Return on assets and equity sit firmly below zero, and EBIT margin runs around -32%. On paper, Twist Bioscience is still paying heavily to grow.

The chart tells a more bullish story. TWST has ripped from the high-$80s and low-$90s into the low-$110s over the last couple of weeks, with 2026/08/05 closing near $112.08 after an intraday high above $113. That’s a strong follow-through after the revenue beat and guidance hike. Intraday action shows tight, controlled trading around $111–$113, signaling orderly demand rather than a one-and-done spike.

With a price-to-sales ratio around 15 and gross margin above 52%, traders are paying up for the TWST growth story. The key now is whether that promised EBITDA breakeven in Q4 actually shows up on the next print.

Why Traders Are Watching TWST Right Now

TWST is in that sweet — and dangerous — zone where growth, guidance, and capital raises collide. On the growth side, Twist Bioscience didn’t just beat Q3 expectations; management turned around and lifted the outlook almost across the board. Q4 revenue is now pegged at $123M–$124M, versus about $117.4M previously expected. For active traders, that kind of “beat-and-raise” pattern is rocket fuel.

Looking further out, TWST raised its fiscal 2026 revenue guidance to $456M–$457M, ahead of prior guidance and Street numbers around the mid-$440Ms. Management also called for gross margin above 52%. That’s critical. When a high-multiple name like Twist Bioscience shows both faster growth and better margins, algorithms and discretionary traders both tend to re-rate the stock higher.

The Street has noticed. TD Cowen bumped its TWST price target from $89 to $115 and stuck with a Buy call after the Q3 beat and guidance move. Baird followed with its own lift to $115 and an Outperform rating. One key detail many traders miss: TD Cowen highlighted that Twist Bioscience expects another year of triple-digit growth in AI-enabled drug discovery orders in FY27. That AI angle gives TWST a narrative hook that momentum traders love to trade around.

But it’s not all sunshine. TWST swung to a larger loss versus last year, and when those numbers first hit, the stock traded down roughly 6% pre-market before recovering. That tells you there are still players uncomfortable with the burn. Then came the upsized $300M offering at $96 per share. Long term, that cash supports R&D, manufacturing expansion, and new products. Short term, it sets a clear reference level around $96 where supply can show up and where dip-buyers may anchor.

In short, Twist Bioscience has become a battleground between growth-focused traders betting on execution and skeptics focused on dilution and red ink — a perfect recipe for volatility.

Conclusion

For active traders, TWST is now a pure execution story. On one hand, Twist Bioscience is guiding Q4 to adjusted EBITDA breakeven, boosting FY26 revenue to the mid‑$450M range, and talking up gross margin above 52%. The company is also guiding toward profitable growth in fiscal 2027. Those are the milestones big funds and fast money both track. If TWST hits them, the stock can justify its premium price-to-sales and keep squeezing shorts.

On the other hand, the cash burn, negative returns on capital, and the $300M equity raise at $96 all remind traders that Twist Bioscience is still in build-out mode. Dilution is real. The wider GAAP loss shows the path to clean profitability won’t be perfectly smooth, regardless of the EBITDA narrative. Any stumble on guidance, AI order growth, or margin expansion, and a richly valued name like TWST can unwind fast.

That’s why the Tim Sykes playbook always applies here: cut losses quickly, trade the chart, and never fall in love with a story. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. As Tim likes to hammer home, “The market doesn’t care about your opinion, only your discipline.” For educational and research-focused traders watching TWST, the edge comes from staying nimble, respecting both the bullish setup and the real downside risk baked into this high-velocity biotech name.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks